FDA approves new Alzheimer's treatment, donanemab from Eli Lilly
Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the ...
FDA approves a new Alzheimer's drug. What to know about Eli Lilly's Kisunla
The FDA approved the experimental Alzheimer's drug donanemab. The drug will be sold under the brand name Kisunla.
FDA approves Alzheimer’s drug donanemab after months of delay
The Food and Drug Administration granted approval Tuesday to a closely watched Alzheimer’s drug, concluding that the benefits ...
FDA approves new drug for Alzheimer’s disease: ‘Meaningful results’
The FDA has approved a new medication for people with Alzheimer’s disease. Eli Lilly’s Kisunla (donanemab) is a once-monthly ...
Alzheimer's Society4d
FDA approves new Alzheimer's disease drug donanemab in the US
Our Director of Research responds to news that the FDA has approved new Alzheimer's disease drug donanemab in the US.
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab
Eli Lilly’s donanemab—to be sold under the brand name Kisunla—received regulatory approval as a monthly injection after an 18 ...
FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of ...
FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
Eli Lilly received FDA approval for a drug to help treat Alzheimer's on Tuesday after studies showed it could help slow the ...
FDA approves Donanemab, new Eli Lilly treatment for early Alzheimer’s disease
A new treatment that could slow Alzheimer’s disease has been approved by the Food and Drug Administration. The drug Donanemab ...
FDA approves new drug to treat Alzheimer's disease
Donanemab (Kisunla), a new drug to treat Alzheimer's disease, was approved by the U.S. Food and Drug Administration on ...
MM&M5d
FDA approves Eli Lilly’s Alzheimer’s drug donanemab under brand name Kisunla
The regulatory greenlight comes less than a month after an FDA advisory committee unanimously backed the drug for approval.
FDA Approves Eli Lilly’s Alzheimer’s Drug
The company says the drug slowed decline in Alzheimer’s patients by 22% compared with a placebo in a large trial.